Updated on 25 November 2013
Tivicay has demonstrated its efficacy in large scale studies covering previously untreated patients as well as patients with advanced treatment histories and resistant to multiple classes of HIV medicines. Tivicay also demonstrated a high barrier to resistance meaning that it is less prone to resistance development.
As for all medicines, Tivicay has been recommended for marketing approval together with a risk management plan (RMP) that aims to manage and minimize the side effects of the medicine. One of the main aspects of the RMP for Tivicay covers the risk of infrequent but potentially severe hypersensitivity (allergic) reactions.